BPC-157
Multi-UseAlso known as: Body Protection Compound-157, Body Protection Compound 157, Pentadecapeptide BPC 157, Stable Gastric Pentadecapeptide BPC 157
Emerging ResearchWhat is BPC-157?
A synthetic 15-amino acid peptide derived from a larger protein found in human gastric juice. BPC-157 is one of the most widely used research peptides in the recovery and biohacking community for musculoskeletal healing and gut repair. The preclinical evidence across tissue types is remarkably consistent — and unusually broad — but human clinical trial data remains limited relative to its popularity.
How it works
BPC-157 activates several overlapping repair pathways simultaneously. Its primary mechanisms include: activation of VEGFR2 (vascular endothelial growth factor receptor 2), which promotes angiogenesis — the formation of new blood vessels critical for tissue repair; modulation of the Akt-eNOS axis, stimulating nitric oxide synthesis to improve microvascular function; ERK1/2 signaling, which supports endothelial cell survival and migration; and NF-kB inhibition, reducing pro-inflammatory cytokine production. In tendon and ligament specifically, BPC-157 activates the FAK-paxillin pathway, which accelerates fibroblast migration into damaged tissue. For gut tissue, it upregulates tight junction proteins (claudins and occludin) and promotes protective mucus production, strengthening intestinal barrier integrity.
What marketers claim
- ▸heals all injuries in days
- ▸replaces surgery for tendons and ligaments
- ▸the most powerful healing peptide available
- ▸completely safe with no side effects
- ▸cures leaky gut permanently
What evidence supports
- ✓robust animal model evidence for accelerated healing of tendons, ligaments, muscle, gut mucosa, bone, and cornea
- ✓Phase 2 human trial for ulcerative colitis showed statistically significant dose-dependent improvement in endoscopic and clinical scores
- ✓small human studies show reduced musculoskeletal pain after injection
- ✓Phase 2 RCT for acute hamstring strain (NCT07437547) registered in 2026 — human musculoskeletal data forthcoming
- ✓2025 systematic review in orthopaedic sports medicine concluded BPC-157 "shows promise for promoting recovery from musculoskeletal injuries"
- ✓2026 PMC review confirmed angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide modulation across multiple tissue types
Research evidence
Key studies on BPC-157, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review
Finding: Systematic review concluded that BPC-157 demonstrates regenerative and cytoprotective effects across animal models for fractures, tendon ruptures, ligament tears, and muscle injuries. A retrospective human study of intraarticular BPC-157 injection for chronic knee pain found 7 of 12 patients reported relief lasting >6 months.
Limitation: Review was of Level IV and V evidence (low-quality human studies and animal data). No RCTs in the musculoskeletal space have been completed. Authors noted the critical need for well-designed human trials.
From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management
Finding: Confirmed that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide modulation, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue. Also reported reduced inflammatory cytokine activity, improved microvascular integrity, and pain modulation through peripheral and dopaminergic mechanisms.
Limitation: Review of preclinical evidence. Authors noted that inconsistent preparation standards, limited clinical validation, and regulatory restrictions underscore the need for rigorous controlled trials.
BPC-157 Phase 2 clinical trial for ulcerative colitis
Finding: Dose-ranging study showed statistically significant, dose-dependent improvement in endoscopic and clinical scores in ulcerative colitis patients receiving BPC-157 compared to placebo.
Limitation: Full publication not yet available in peer-reviewed form. Ulcerative colitis results may not directly predict outcomes for other gut or musculoskeletal applications.
Phase 2 RCT: BPC-157 for acute hamstring muscle strain repair (NCT07437547)
Finding: Randomized, double-blind, placebo-controlled Phase 2 study underway to evaluate whether BPC-157 can speed structural healing and functional recovery after acute Grade II hamstring strain. Co-primary endpoints are time to return to unrestricted sport and MRI-assessed injury volume at Day 14.
Limitation: Trial is currently enrolling — no results available yet. This is the first controlled human musculoskeletal trial of BPC-157.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Week 1–2
Based on animal models showing early upregulation of angiogenic and repair genes within 48–72 hours of administration. Users with gut-related applications (oral BPC-157 for intestinal healing) often report the earliest subjective improvement in this window. No controlled human timeline data exists at this stage.
Week 2–4
In the ulcerative colitis Phase 2 trial, endoscopic improvement was measurable at the first post-treatment assessment. For musculoskeletal applications, animal data suggests peak fibroblast activation and initial tendon remodeling occurring in this window.
Month 1–3
Animal tendon repair models show measurable tensile strength recovery in this range. Anecdotal human reports from practitioners using BPC-157 for tendon and ligament injuries most commonly describe meaningful functional improvement between 4–12 weeks.
Month 3+
Tissue remodeling requires time regardless of the healing signal — BPC-157 appears to accelerate the process, not bypass it. Return to full loading of a healed tendon or ligament requires appropriate rehabilitation alongside any peptide protocol.
Safety notes & concerns
Full safety guide →- ⚠no completed large-scale human safety trials — preclinical safety data is reassuring but not a substitute
- ⚠banned by WADA since 2022 — competitive athletes are ineligible to use it
- ⚠not FDA approved for any indication
- ⚠unregulated supply chain — purity, concentration accuracy, and sterility are not guaranteed from research peptide suppliers
- ⚠half-life is under 30 minutes — frequent injection increases infection risk with repeated subcutaneous administration
Pairs well with
Use caution with
Frequently asked questions
Is BPC-157 safe to use?
Preclinical safety data is reassuring — animal studies have not identified an LD1 even at very high doses, and no major adverse effects were found across organ systems. However, there are no completed large-scale human safety trials. The unknowns include long-term effects in humans, drug interactions, and the safety profile in populations with specific health conditions. Use under physician supervision is strongly recommended.
What is the difference between injectable and oral BPC-157?
Route of administration affects where the peptide concentrates. Subcutaneous or intramuscular injection delivers BPC-157 systemically and achieves higher plasma concentrations — preferred for musculoskeletal healing where the effect needs to reach tendons, ligaments, and muscles. Oral administration delivers the peptide directly to the gastrointestinal tract, where some intact peptide is absorbed through the intestinal wall despite enzymatic degradation — preferred for gut healing and intestinal permeability issues.
Why is BPC-157 banned by WADA?
WADA added BPC-157 to its prohibited list in 2022 under the category of peptide hormones, growth factors, related substances, and mimetics. The ban is based on significant evidence that BPC-157 promotes tissue repair and recovery, which WADA considers a performance-enhancing advantage in competitive sport. The ban applies to in-competition and out-of-competition use.
Can BPC-157 repair a torn tendon or ligament without surgery?
BPC-157 has shown accelerated healing in animal models of tendon and ligament injury, including complete transection of the Achilles tendon in rats. Whether this translates to clinical outcomes in complete human tendon or ligament tears is unknown — no human RCT has tested this specific question. For partial injuries and chronic tendinopathies, the human case series data is more encouraging. A complete rupture that would otherwise require surgical repair should not be managed with BPC-157 as a substitute for proper orthopaedic assessment.
How does BPC-157 compare to TB-500?
BPC-157 and TB-500 (Thymosin Beta-4) are distinct peptides with complementary mechanisms that are frequently stacked. BPC-157 primarily works locally — promoting angiogenesis, fibroblast activation, and collagen synthesis at the site of injury through VEGFR2 and FAK pathways. TB-500 promotes systemic cell migration and actin regulation, helping undifferentiated repair cells travel to injury sites. The combination is thought to provide a more complete repair signal than either peptide alone, though this stack has not been tested in controlled human trials.
What does the 2026 PCAC reclassification mean?
In July 2026, BPC-157 was reclassified from Category 2 back to Category 1 by the relevant regulatory review body. This is a research access classification, not a therapeutic approval. Category 1 status makes BPC-157 more accessible to academic researchers studying it in clinical trials, which may accelerate the human data that is currently the main gap in the evidence base. It does not mean BPC-157 is approved for clinical use.
Products containing BPC-157
Related multi-use peptides
post-procedure recovery, aging skin, thinning hair
investigational use in musculoskeletal recovery and tissue repair protocols, typically in combination with BPC-157, under physician supervision — with full understanding that human efficacy data for the TB-500 fragment specifically does not yet exist
antioxidant support, glycation protection, aging skin
Further reading
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with BPC-157
Last updated: 2026-07-01
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.